Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies.

@article{Diehl2007EarlyIA,
  title={Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies.},
  author={Volker Diehl and Michael Fuchs},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2007},
  volume={18 Suppl 9},
  pages={
          ix71-9
        }
}
Treatment strategies of early stage Hodgkin lymphoma (HL) have changed during recent years. Until recently, extended field (EF) irradiation has been considered the standard treatment. However, due to the recognition of the high relapse rate and the fatal long-term effects, EF radiotherapy (radiation to initially involved and adjacent lymph node areas) is now being abandoned by most study groups. Instead, for favourable early stage disease, short duration chemotherapy for control of occult… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
VIEW 2 EXCERPTS
CITES RESULTS & BACKGROUND

Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.

Sara Aquino, Marino Clavio, +18 authors Marco Gobbi
  • Oncology letters
  • 2011

18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

Gerard Moulin-Romsee, Elif Hindié, +9 authors Jean-luc Moretti
  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2009
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

  • The New England journal of medicine
  • 2003
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.

Simonetta Viviani, Gianni Bonadonna, +5 authors Pinuccia Valagussa
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

BEACOPP Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12Trials of the German Hodgkin Study Group (GHSG)

V Diehl, C Brilliant, J Franklin
  • Blood
  • 2004
VIEW 2 EXCERPTS

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
VIEW 1 EXCERPT